

WHO GUIDE TO COST-EFFECTIVENESS ANALYSIS

CONTENTS

The graphic on the cover is a stylized representation of Figure 5 in Background Paper 7 showing uncertainty analysis.

MAKING CHOICES IN HEALTH:

WHO GUIDE TO

COST-EFFECTIVENESS ANALYSIS

EDITED BY

T. TAN-TORRES EDEJER, R. BALTUSSEN, T. ADAM,
R. HUTUBESSY, A. ACHARYA, D.B. EVANS AND
C.J.L. MURRAY



World Health Organization
Geneva

WHO Library Cataloguing-in-Publication Data

World Health Organization.

Making choices in health: WHO guide to cost-effectiveness analysis/
edited by T. Tan-Torres Edejer ... [et al.]

- | | |
|------------------------------------|--------------------------------------|
| 1. Cost-benefit analysis – methods | 2. Health care rationing – economics |
| 3. Decision making | 4. Health priorities – economics |
| 5. Models, Econometric | 6. Guidelines |
| I. Tan-Torres Edejer, Tessa. | II. WHO-CHOICE III. Title. |

ISBN 92 4 154601 8

(LC/NLM classification: HD 47.4)

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications—whether for sale or for noncommercial distribution—should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Printed in Switzerland

CONTENTS

Preface	IX
List of Acronyms and Abbreviations	XXI
PART ONE: METHODS FOR GENERALIZED COST-EFFECTIVENESS ANALYSIS	
1. What is Generalized Cost-Effectiveness Analysis?	3
2. Undertaking a study using GCEA	17
3. Estimating costs	29
4. Estimating health effects	49
5. Discounting	67
6. Uncertainty in cost-effectiveness analysis	73
7. Policy uses of Generalized CEA	83
8. Reporting CEA results	91
9. Summary of recommendations	93
References	97
Annex A. WHO-CHOICE activities on Generalized Cost-Effectiveness Analysis	
Annex B. Draft list of intervention clusters for evaluation by WHO-CHOICE	107 110
Annex C. An illustration of the types of costs included in a selection of intervention activities at central levels	111
Annex D. Interpreting international dollars	112
Annex E. DALYs to measure burden of disease	113
Annex F. Measuring intervention benefit at the population level	115
Annex G. Epidemiological subregions as applied in WHO Generalized CEA	118
Endnotes	119

PART TWO: BACKGROUND PAPERS AND APPLICATIONS

1.	Development of WHO guidelines on generalized cost-effectiveness analysis	125
	<i>Christopher J.L. Murray, David B. Evans, Arnab Acharya, Rob M.P.M. Baltussen</i>	
2.	PopMod: A longitudinal population model with two interacting disease states	151
	<i>Jeremy A. Lauer, Klaus Röhrich, Harold Wirth, Claude Charette, Steve Gribble, Christopher J.L. Murray</i>	
3.	Programme costs in the economic evaluation of health interventions	177
	<i>Benjamin Johns, Rob Baltussen, Raymond Hutubessy</i>	
4.	Econometric estimation of country-specific hospital costs	197
	<i>Taghreed Adam, David B. Evans, Christopher J.L. Murray</i>	
5.	Stochastic league tables: communicating cost-effectiveness results to decision-makers	217
	<i>Raymond C.W. Hutubessy, Rob M.P.M. Baltussen, David B. Evans, Jan J. Barendregt, Christopher J.L. Murray</i>	
6.	Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables	225
	<i>Rob M.P.M. Baltussen, Raymond C.W. Hutubessy, David B. Evans, Christopher J.L. Murray</i>	
7.	Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk	237
	<i>Christopher J.L. Murray, Jeremy A. Lauer, Raymond C.W. Hutubessy, Louis Niessen, Niels Tomijima, Anthony Rodgers, Carlene M.M. Lawes, David B. Evans</i>	
8.	Generalized cost-effectiveness analysis: an aid to decision making in health	277
	<i>Raymond C.W. Hutubessy, Rob M.P.M. Baltussen, Tessa Tan-Torres Edejer, David B. Evans</i>	
9.	Ethical issues in the use of cost effectiveness analysis for the prioritization of health care resources	289
	<i>Dan W. Brock</i>	
	Index	313

ACKNOWLEDGEMENTS

Many individuals have contributed to the refinement of the framework, methods and tools for generalized cost-effectiveness analysis. Their contributions are recognized collectively under the name WHO-CHOICE Collaboration. In addition to them, a number of experts provided valuable input in anonymous reviews for the published papers, during the consultative meeting in Geneva in 2001, and during other scientific meetings where WHO-CHOICE or generalized cost-effectiveness analysis was presented. Their contributions are gratefully acknowledged. Another important source of feedback has been the policy-makers and analysts from many different countries who have attended the workshops on generalized cost-effectiveness analysis that we have conducted over the past years. Close interaction with them as they applied the tools and techniques gave us insights into a range of concerns from a user's perspective, and made us aware of the need to be responsive to different audiences.

Lastly, we would like to give special thanks to Margaret Squadrani, Marilyn Vogel, Kai Lashley and Keith Wynn who, with their dedication, patience and painstaking attention to detail, made the actual production of the book possible.

This guide benefited from the input of many experts, including those participating in a meeting on Methods for Cost-Effectiveness Analysis held in Geneva in January 2002. Those who participated were:

Dr Arnab Acharya, The Institute of Development Studies, UK
Dr Jan Barendregt, Erasmus University, The Netherlands
Dr Stephen Birch, McMaster University, Canada
Dr Dan Brock, National Institutes of Health, USA
Dr Werner Brouwer, Erasmus University Rotterdam, The Netherlands
Dr Vilma Carande-Kulis, Centers for Disease Control & Prevention, USA
Dr Michael Drummond, University of York, UK
Dr Alastair Gray, University of Oxford, UK
Dr Paul Kind, University of York, UK
Dr Martin Meltzer, Centers for Disease Control and Prevention, USA
Dr Mark Miller, National Institutes of Health, USA
Professor Anne Mills, London School of Hygiene & Tropical Medicine, UK
Dr Raul Molina, Universidad Autonoma Metropolitana-Iztapalapa, Mexico
Dr Benjamin Nganda, University of Nairobi, Kenya
Dr Louis Niessen, Erasmus University, The Netherlands
Dr Max Price, University of the Witwatersrand, South Africa
Professor Jeff Richardson, Centre for Health Programme Evaluation, Australia
Dr Juan Rovira, The World Bank, USA
Dr Orville Solon, University of the Philippines, Philippines
Dr Sirinen Sunakankunti, Chulalongkorn University, Thailand

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30245

